Neuralstem announces treatment of first ALS patient with spinal cord stem cells

Neuralstem, Inc. (NYSE Amex: CUR) announced that the first ALS patient was treated with its spinal cord stem cells yesterday at the Emory ALS Center at Emory University, in Atlanta, GA.  A total of up to 18 patients is planned to be treated in this first U.S. clinical trial to evaluate human neural stem cells for the treatment of ALS (Amyotrophic Lateral Sclerosis, or Lou Gehrig's disease).  ALS affects roughly 30,000 people in the U.S., with about 5,600 new diagnoses per year, according to the ALS Association.

"The treatment of the first patient with our spinal cord stem cells represents a significant milestone for the Company," said Neuralstem President and CEO, Richard Garr.  

"Our scientists have worked tirelessly to bring our discovery of adherent neural stem cells from the bench to the bedside," said Dr. Karl Johe, Chairman of the Board and Chief Scientific Officer at Neuralstem, and the inventor of the technology. "This trial aims to establish the safety and feasibility of using our cells to treat ALS.  For now, we are focused on the safe and speedy recovery of the first patient, and we wish to thank him and his family for their courageous participation in the trial."

SOURCE Neuralstem, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Miniature brains that can move muscles, grown in the lab